Document is current
Any future updates will be listed below
-
Authors
Muilu, Paula
Rantalaiho, Vappu
Kautiainen, Hannu
Virta, Lauri J.
Eriksson, Johan G.
Puolakka, Kari
-
Funding
Funding for this research was provided by:
Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (9U050)
Finnish Rheumatology Research Foundation (-)
Tampereen Reumayhdistys (-)
Suomen Kulttuurirahasto (-)
- License Information
-
More Information
Article History
Received: 8 November 2019
Accepted: 30 March 2020
First Online: 3 July 2020
Ethics approval and consent to participate
: Only unidentifiable register data were used and patients were not contacted, thus the Finnish legislation did not require an approval by an ethics committee.
: Not applicable.
: Dr. Muilu reports a Congress trip from UCB Pharma, a Congress trip from MSD Finland and a congress trip from Sanofi Genzyme outside the submitted work. Dr. Rantalaiho reports a speaker’s honorarium and a congress trip from Pfizer, a congress trip from Celegen and a congress trip from Mylan outside the submitted work. Dr. Puolakka, Dr. Virta, Dr. Eriksson, and Mr. Kautiainen have nothing to disclose.
